Reader Poll

How would you treat ... recurrent pre-B ALL in a 24-year-old woman?

An interactive reader dialog hosted by Hematology News’ Editor in Chief, Dr. Matt Kalaycio


Welcome to our new online feature, "How would you treat?"
This new item seeks to stimulate a lively conversation around cases that address the "art of medicine," in which there are no right or wrong ways to treat a specific patient. Instead, we posit to you "if this was your patient, how would you treat her?" The goal is to offer each other our thoughts on how we view treatment options from the perspectives of potential for cure and quality of life for a specific patient given his or her unique treatment history.

Our first case for your consideration will examine perspectives on the treatment of recurrent acute lymphoblastic leukemia, a condition with increasing therapeutic options.

A 24-year-old female was diagnosed with pre-B Acute Lymphoblastic Leukemia. She achieved complete remission on a standard chemotherapy protocol that included L-asparaginase and completed maintenance therapy 1 year ago, but no tests for MRD were performed. Routine surveillance blood counts worsened and a bone marrow biopsy confirms relapse. She feels well. There is no detectable BCR/ABL, but the leukemic blasts express CD19, CD20, and CD22. She has an HLA-matched sibling donor. Her exam is normal with WBC 23,000 (76% Blasts), Hgb 10.3, Plt 32K.

Dr. Matt Kalaycio

Assuming all of the following treatment choices are readily available with adequate insurance coverage, which would you recommend next? After selecting your treatment choice, please click on the black Comments box below and explain the reasoning behind your choice.

Recommended Reading

CB-5083 showed significant activity against B-ALL
MDedge Hematology and Oncology
Immune status linked to outcomes of CAR T-cell therapy
MDedge Hematology and Oncology
Report details progress, obstacles in cancer research and care
MDedge Hematology and Oncology
CCSs have higher burden of chronic conditions
MDedge Hematology and Oncology
FDA approves first CAR T-cell therapy to treat ALL
MDedge Hematology and Oncology
   Comments ()